The research of the InterTAK Study Group, led by Professor Templin, has made an important contribution to the current knowledge and understanding of Takotsubo syndrome.
While clinical studies based on the InterTAK registry were able to provide a better clinical characterization of TTS and provide prognostic information about short- and longterm outcomes, as well as hints on basic pathophysiological causes, many important questions regarding the syndrome still remain unanswered. For us some of these main questions concern the role of biomarkers in the diagnosis of TTS, the role of genetics in the susceptibility to the disease, and most importantly, whether there are specific therapeutic options. While holding the largest biobank on Takotsubo syndrome to date, the aim of our research is the identification of novel biomarkers on the level of small molecules, (nc)RNAs and proteins, as well as the identification of genetic and epigenetic factors that influence the susceptibility of patients to develop Takotsubo Syndrome. Moreover, we aim to test promising therapeutic options in in-vitro and in-vivo experimental studies as well as to make further progress in understanding the molecular mechanisms of this very unique disease.
Figure 1. Timecourse of the InterTAK blood collection and planned analyses.